HomepageEVOTF • OTCMKTS
add
Evotec
Vorige slotkoers
$Â 8,27
Jaar-range
$Â 5,98 - $Â 12,60
Beurswaarde
1,49Â mld. USD
Koers/winst
-
Dividendrendement
-
Primaire beurs
ETR
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 221,23Â mln. | 9,89% |
Bedrijfskosten | 44,92Â mln. | 153,47% |
Netto inkomsten | -40,84Â mln. | -153,17% |
Netto winstmarge | -18,46 | -130,46% |
Winst per aandeel | — | — |
EBITDA | 6,62Â mln. | -69,72% |
Effectief belastingtarief | -157,42% | — |
Balans
Totale activa
Totale passiva
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 396,80Â mln. | -34,32% |
Totale activa | 1,91Â mld. | -15,09% |
Totale passiva | 959,98Â mln. | -15,24% |
Totaal aandelenvermogen | 952,52 mln. | — |
Uitstaande aandelen | 177,39 mln. | — |
Koers-boekwaardeverhouding | 1,54 | — |
Rendement op activa | 0,15% | — |
Rendement op kapitaal | 0,21% | — |
Kasstroom
Nettomutatie in liquide middelen
(EUR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -40,84Â mln. | -153,17% |
Operationele kasstroom | 74,22Â mln. | 272,14% |
Kasstroom uit beleggingen | 16,92Â mln. | 156,40% |
Kasstroom uit financiering | -29,33Â mln. | -226,92% |
Nettomutatie in liquide middelen | 75,09Â mln. | 550,51% |
Vrije kasstroom | 132,68Â mln. | 336,44% |
Over
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Opgericht
1993
Website
Werknemers
4.740